Atezolizumab (Tecentriq®) for triple-negative breast cancer.
Atezolizumab in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 03/07/2019 |
| Rapid review completed | 19/07/2019 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by the HSE | 30/07/2019 |
| Pre-submission consultation with Applicant | 07/10/2019 |
| Initial submission received from Applicant | 09/12/2019 |
| Complete submission received from Applicant | 13/01/2020 |
| Preliminary review sent to Applicant | 05/05/2020 |
| NCPE assessment re-commenced | 29/05/2020 |
| Factual accuracy check sent to Applicant | 06/08/2020 |
| NCPE assessment re-commenced | 14/08/2020 |
| NCPE assessment completed | 01/09/2020 |
| NCPE assessment outcome | The NCPE recommends that atezolizumab (Tecentriq®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.